Navigation Links
Rheumatoid Arthritis Market Forecast
Date:9/20/2011

NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Rheumatoid Arthritis Market Forecast

http://www.reportlinker.com/p0360301/Rheumatoid-Arthritis-Market-Forecast.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The launch of novel oral drugs and reformulations of current brands are expected to fuel growth across the seven major markets, rising from $12bn in 2010 to $18bn by 2020. TNF inhibitors will remain dominant market players, but the growing enthusiasm for non-TNF biologics at earlier lines of therapy is predicted to continue over the next decade and serves as an additional growth driver.Gain insight into the RA competitive landscape and assess commercial opportunity using 10 year patient-based forecasts with clear methodology.Access current and future patient-numbers and expand knowledge on potential future events that may impact these.Evaluate existing and potential future brand dynamics by line of therapy; from first- through to fourth-line and beyond.Enhance understanding of future product potential, with key opinion leader views of late stage kinase inhibitors, such as tofacitinib and FosD.Gauge the anticipated impact of reformulations on patient switching and the subsequent effect on total brands sales.With two novel kinase inhibitors forecast to launch for rheumatoid arthritis and key brand reformulations set to enter the market over the next decade, Datamonitor's patient-based forecast shows that the market will grow to reach $18bn in 2020.Despite news of deaths in a Phase III trial of Pfizer's tofacitinib, physicians remain upbeat on this potential game-changer, stating that while safety is a concern for new drugs, the deaths mirror those seen in the era prior to biologics. Datamonitor forecasts favorable uptake of tofacitinib, reaching sales of $1.2bn by 2020 in the major markets.Opinion leaders verify rising interest to adopt non-TNF biologics earlier in the algorithm, due to familiarity and more experience of their side-effects. With Bristol-Myers Squibb gaining US approval of subcutaneous Orencia (abatacept) in July 2011, this reformulation adds positively to its lifecycle and it will benefit from this projected trend.What impact has the deaths in a Phase III trial of tofactinib had on its potential future uptake across the seven major rheumatoid arthritis markets?What is the future outlook in terms of patients and sales for 2009 market entrants Cimzia and Simponi and how does this compare to older TNF brands?How will the launch of subcutaneous formulations of marketed intravenous drugs Orencia and Actemra change their usage and impact future brand sales?How will first-, second-, third- and fourth-line and beyond biologic brand dynamics change in the rheumatoid arthritis markets over the coming decade?How will each of the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) evolve in terms of patients from 2010 to 2020?

To order this report:

Pathology Industry: Rheumatoid Arthritis Market Forecast

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
10. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 The U.S. Food and Drug Administration today ... (CIC) in adult patients. "No one medication ... Julie Beitz , M.D., director of the Office of ... and Research. "With the availability of new therapies, patients and ... condition." ...
(Date:1/19/2017)... CITY, N.J. , Jan. 19, 2017 ... over $100 for their medication when a pharmacy just ... same exact prescription.  To alleviate this problem Medicationdiscountcard.com ... and patients to see exactly how much their medication ... Comparison Shopping Made Easy ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to ... with big-name retail buyers at the January ECRM Trade Show in Hilton Head, SC. ... utmost safety standards in all of its creations to help create a more traditional ...
(Date:1/21/2017)... ... ... the perfect set of tools for video editors that want to create the illusion of ... CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic depth ... focus from one area into the next. ProDOF comes with 0.5 second, 1.0 second, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa ... in Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three ... medicine and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
(Date:1/20/2017)... ... 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted ... world. Yisrayl says this generation is a time like no other and society needs to ... , Yisrayl says he does not want to sound like an old bible beater because ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based ... recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting from ... large range of supplements that keep the body functioning at its peak performance ...
Breaking Medicine News(10 mins):